3 citations
,
June 2025 in “Biomedical Reports” Nanotechnology can improve cervical cancer treatment by targeting drugs better and reducing side effects.
June 2021 in “Research Square (Research Square)” Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
November 2025 in “Journal of Investigative Dermatology” IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.
26 citations
,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
2 citations
,
May 2025 in “IntechOpen eBooks” Early treatment with corticosteroids and immunosuppressants is crucial for managing Vogt-Koyanagi-Harada disease.
23 citations
,
March 2017 in “PTR. Phytotherapy research/Phytotherapy research” Butin is effective in treating vitiligo in mice.
Gingerol may help treat chronic graft-versus-host disease by improving immune cell balance.
December 2022 in “Small methods” A new hair loss treatment using dissolving microneedles was found to speed up hair growth and was more effective than daily use of common hair growth drugs.
January 2024 in “Wiadomości Lekarskie” New markers can detect tumors, aid drug delivery, and treat cancer effectively and safely.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Simvastatin helps hair regrowth in autoimmune alopecia by directly affecting T cells.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
32 citations
,
May 2023 in “Frontiers in Immunology” Understanding cellular interactions in VCA may lead to better treatments and reduce rejection.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
January 2007 in “Frontiers in Medicine” Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
September 2021 in “Assay and drug development technologies” Drug repurposing shows promise for treating many medical conditions.
March 2025 in “International Journal of Molecular Sciences” Veratric Acid may help promote hair growth and reduce hair loss.
August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
2 citations
,
December 2022 in “PNAS nexus” SCD-153 shows promise as an effective topical treatment for alopecia areata.
August 2025 in “Skin Appendage Disorders” Low-dose oral minoxidil might help with hair loss during chemotherapy, but more research is needed.
1 citations
,
May 2006 in “Expert Opinion on Therapeutic Patents” No FDA-approved treatments for chemotherapy-induced hair loss existed in 2006; more research was needed.
15 citations
,
July 2022 in “Nano Research” A cholesterol-free liposomal platform using protopanaxadiol effectively promotes hair growth and treats alopecia.
January 2018 in “Journal of the advanced practitioner in oncology” Older patients with advanced kidney cancer can be managed with a drug called Sunitinib.
7 citations
,
July 2018 in “Journal of Functional Biomaterials” A new anti-baldness patch effectively treats hair loss by blocking enzymes linked to the condition.
14 citations
,
November 2016 in “Annals of Internal Medicine” Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
November 2025 in “Zenodo (CERN European Organization for Nuclear Research)” November 2025 in “Zenodo (CERN European Organization for Nuclear Research)” 1 citations
,
March 2009 in “The Journal of Urology” Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.
2 citations
,
May 2011 in “Journal of Clinical Oncology” Further testing of paclitaxel poliglumex for this cancer treatment is not justified.